Literature DB >> 26405593

A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.

Hélène Sicard1, Cécile Bonnafous1, Ariane Morel1, Martine Bagot2, Armand Bensussan2, Anne Marie-Cardine2.   

Abstract

Cutaneous T-cell lymphomas (CTCLs) represent a group of rarely occurring and clinically and pathologically heterogeneous diseases that are considered incurable at advanced stages. Current treatments provide limited clinical benefit and are thus largely amenable to improvement. An antibody-based CTCL-specific immunotherapy targeting the KIR3DL2 receptor expressed by the tumor cells in CTCL is currently under development and has shown encouraging results in pre-clinical studies.

Entities:  

Keywords:  Antibody; CTCL; KIR3DL2; immunotherapy; non-clinical studies

Year:  2015        PMID： 26405593      PMCID： PMC4570095          DOI： 10.1080/2162402X.2015.1022306

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor.

Authors:  M Bagot; A Moretta; S Sivori; R Biassoni; C Cantoni; C Bottino; L Boumsell; A Bensussan
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

2.  IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma.

Authors:  Anne Marie-Cardine; Nicolas Viaud; Nicolas Thonnart; Rachel Joly; Stéphanie Chanteux; Laurent Gauthier; Cécile Bonnafous; Benjamin Rossi; Mathieu Bléry; Carine Paturel; Armand Bensussan; Martine Bagot; Hélène Sicard
Journal:  Cancer Res       Date:  2014-11-01       Impact factor: 12.701

Review 3.  NK cell MHC class I specific receptors (KIR): from biology to clinical intervention.

Authors:  Ariane Thielens; Eric Vivier; François Romagné
Journal:  Curr Opin Immunol       Date:  2012-01-20       Impact factor: 7.486

4.  Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis.

Authors:  A T Chan; S D Kollnberger; L R Wedderburn; P Bowness
Journal:  Arthritis Rheum       Date:  2005-11

5.  Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.

Authors:  Nouhoum Sako; Valérie Schiavon; Touda Bounfour; Valérie Dessirier; Nicolas Ortonne; Daniel Olive; Caroline Ram-Wolff; Laurence Michel; Hélène Sicard; Anne Marie-Cardine; Martine Bagot; Armand Bensussan; Christian Schmitt
Journal:  Cytometry A       Date:  2014-07-18       Impact factor: 4.355

Review 6.  Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Authors:  Ellen J Kim; Stephen Hess; Stephen K Richardson; Sara Newton; Louise C Showe; Bernice M Benoit; Ravi Ubriani; Carmela C Vittorio; Jacqueline M Junkins-Hopkins; Maria Wysocka; Alain H Rook
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

Review 7.  WHO-EORTC classification for cutaneous lymphomas.

Authors:  Rein Willemze; Elaine S Jaffe; Günter Burg; Lorenzo Cerroni; Emilio Berti; Steven H Swerdlow; Elisabeth Ralfkiaer; Sergio Chimenti; José L Diaz-Perez; Lyn M Duncan; Florent Grange; Nancy Lee Harris; Werner Kempf; Helmut Kerl; Michael Kurrer; Robert Knobler; Nicola Pimpinelli; Christian Sander; Marco Santucci; Wolfram Sterry; Maarten H Vermeer; Janine Wechsler; Sean Whittaker; Chris J L M Meijer
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

Review 8.  Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.

Authors:  L Alinari; R Lapalombella; L Andritsos; R A Baiocchi; T S Lin; J C Byrd
Journal:  Oncogene       Date:  2007-05-28       Impact factor: 9.867

Review 9.  Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).

Authors:  Elise Olsen; Eric Vonderheid; Nicola Pimpinelli; Rein Willemze; Youn Kim; Robert Knobler; Herschel Zackheim; Madeleine Duvic; Teresa Estrach; Stanford Lamberg; Gary Wood; Reinhard Dummer; Annamari Ranki; Gunter Burg; Peter Heald; Mark Pittelkow; Maria-Grazia Bernengo; Wolfram Sterry; Liliane Laroche; Franz Trautinger; Sean Whittaker
Journal:  Blood       Date:  2007-05-31       Impact factor: 22.113

10.  TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma.

Authors:  Emmanuella Guenova; Rei Watanabe; Jessica E Teague; Jennifer A Desimone; Ying Jiang; Mitra Dowlatshahi; Christoph Schlapbach; Knut Schaekel; Alain H Rook; Marianne Tawa; David C Fisher; Thomas S Kupper; Rachael A Clark
Journal:  Clin Cancer Res       Date:  2013-06-19       Impact factor: 12.531
  10 in total
  8 in total

1.  Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma.

Authors:  Bethany Mundy-Bosse; Nathan Denlinger; Eric McLaughlin; Nitin Chakravarti; Susan Hwang; Li Chen; Hsiaoyin Charlene Mao; David Kline; Youssef Youssef; Rebecca Kohnken; Dean Anthony Lee; Gerard Lozanski; Aharon G Freud; Pierluigi Porcu; Basem William; Michael A Caligiuri; Anjali Mishra
Journal:  Blood Adv       Date:  2018-08-14

Review 2.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

3.  Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients.

Authors:  Philippe Lefrançois; Pingxing Xie; Linghua Wang; Michael T Tetzlaff; Linda Moreau; Andrew K Watters; Elena Netchiporouk; Nathalie Provost; Martin Gilbert; Xiao Ni; Denis Sasseville; David A Wheeler; Madeleine Duvic; Ivan V Litvinov
Journal:  Oncoimmunology       Date:  2018-05-31       Impact factor: 8.110

Review 4.  Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas.

Authors:  Christian Schmitt; Anne Marie-Cardine; Armand Bensussan
Journal:  Front Immunol       Date:  2017-08-30       Impact factor: 7.561

Review 5.  New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.

Authors:  Kazuyasu Fujii
Journal:  Front Oncol       Date:  2018-06-04       Impact factor: 6.244

Review 6.  Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives.

Authors:  Malgorzata Bobrowicz; Radoslaw Zagozdzon; Joanna Domagala; Roberta Vasconcelos-Berg; Emmanuella Guenova; Magdalena Winiarska
Journal:  Cancers (Basel)       Date:  2019-09-24       Impact factor: 6.639

Review 7.  Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.

Authors:  Carlos Cuesta-Mateos; Ana Alcaraz-Serna; Beatriz Somovilla-Crespo; Cecilia Muñoz-Calleja
Journal:  Front Immunol       Date:  2018-01-17       Impact factor: 7.561

8.  Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation.

Authors:  Ieva Saulite; Desislava Ignatova; Yun-Tsan Chang; Christina Fassnacht; Florentia Dimitriou; Eleni Varypataki; Florian Anzengruber; Mirjam Nägeli; Antonio Cozzio; Reinhard Dummer; Julia Scarisbrick; Steve Pascolo; Wolfram Hoetzenecker; Malgorzata Bobrowicz; Emmanuella Guenova
Journal:  Oncoimmunology       Date:  2020-03-18       Impact factor: 8.110
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.